期刊
ONCOIMMUNOLOGY
卷 6, 期 4, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1294296
关键词
Antibodies; B cells; humoral response; immunoglobulins; immunosurveillance; melanoma; tumor microenvironment
资金
- National Institute for Health Research (NIHR) BRC at Guy's and St. Thomas' NHS Foundation Trust and King's College London
- Medical Research Council [MR/L023091/1]
- British Skin Foundation [S633]
- Dermatrust
- Guy's and St. Thomas's Charity Melanoma Special Fund
- Cancer Research UK [C30122/A11527, C30122/A15774]
- Academy of Medical Sciences
- CR UK/EPSRC/MRC/NIHRKCL/UCL Comprehensive Cancer Imaging Centre [C1519/A10331]
- Breakthrough Breast Cancer/Breast Cancer Now [147]
- CR UK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre [C10355/A15587]
- MRC [MR/L023091/1, 1820762] Funding Source: UKRI
- Medical Research Council [MR/L023091/1] Funding Source: researchfish
Evidence of tumor-resident mature B cell and antibody compartments and reports of associations with favorable prognosis in malignant melanoma suggest that humoral immunity could participate in antitumor defense. Likely striving to confer immunological protection while being subjected to tumor-promoting immune tolerance, B cells may engender multiple functions, including antigen processing and presentation, cytokine-mediated signaling, antibody class switching, expression and secretion. We review key evidence in support of multifaceted immunological mechanisms by which B cells may counter or contribute to malignant melanoma, and we discuss their potential translational implications. Dissecting the contributions of tumor-associated humoral responses can inform future treatment avenues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据